

Our Health Outcomes Impact



Johnson & Johnson (J&J) MedTech plays a critical role in helping to elevate the standard of care for patients and the medical community by striving to improve health outcomes as standard practice across the industry. These outcomes include reduced costs, altered disease trajectories, and improved patient outcomes. And, throughout the global pandemic, they include not just maintaining our healthcare system during a time of crisis but bolstering its ability to adapt and respond.

In 2021, our products were used in operating rooms across the U.S. to provide millions of people with safe surgeries and effective disease treatment,¹ including reducing the risks of surgical site infections^{2,3} and reducing leaks during colorectal procedures,⁴ as well as to treat atrial fibrillation,⁵ obesity,^{6,7} and knee⁸ and hip osteoarthritis.⁹ Use of our products resulted in better outcomes,¹⁰ including reduced complications,^{11,12} decreased pain,¹³ fewer emergency room visits,¹⁴ lower mortality rates,¹⁵ faster recovery,¹⁶ and improved quality of life.¹⁷ An especially notable example of the way we continued ***Elevating the Standard of Care to Improve Patient Outcomes*** in 2021: the National Institute for Health and Care Excellence (NICE) issued a new medical technologies guidance recommending adopting our Plus Sutures as part of a bundle of care for preventing surgical site infection in the National Health Service (NHS).¹⁸ NICE's robust evidence-based approach to medical technology assessment has generated international recognition of its recommendations, including by U.S. payors.

As healthcare centers across the world continued to grapple with the COVID-19 pandemic throughout 2021, so did our commitment to ***Persevering and Contributing During Extraordinary Times***. We supported hospitals and healthcare systems in their COVID response, including providing frontline workers with resources, training, and supplies. We also supported hospitals and healthcare systems in their delivery of non-COVID care, including deploying mobile training labs to surgeons across the United States offering education and skill development opportunities in general surgery, robotic-assisted surgery, and consistent surgical process.

We remain as driven as ever by our passion to continuously drive better outcomes and create greater value for patients, providers, and payors alike, elevating existing gold standards ever higher.

This is part of the Johnson & Johnson MedTech series, "Advancing Health, Improving Lives." To view more information on how J&J MedTech is driving Innovation, Health Outcomes, and Social Impact, visit www.jnjmedtech.com/impact.

References

1. Data are an approximate number according to Johnson & Johnson U.S. internal unit volume across platforms and an approximate number of patients in the U.S. using J&J vision products.
2. de Jonge SW, Atema JJ, Solomkin JS, Boermeester MA. Meta-analysis and trial sequential analysis of triclosan-coated sutures for the prevention of surgical site infection. *Brit J Surg.* 2017; 104(2):e118-e133. doi: 10.1002/bjs.10445
3. NICE 2021. Medical Technologies Guidance: Plus Sutures for preventing surgical site infection. Available from: <https://www.nice.org.uk/guidance/mtg59/resources/plus-sutures-for-preventing-surgical-site-infection-pdf-64372124642245>. Accessed April 1, 2022. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
4. Pla-Martí V, Martín-Arévalo J, Moro-Valdezate D, et al. Impact of the novel powered circular stapler on risk of anastomotic leakage in colorectal anastomosis: a propensity score-matched study. *Tech Coloproctol.* 2021;25(3):279-284.
5. Schilling, R Dhillon G, Tondo C, et al. Safety, effectiveness, and quality of life following pulmonary vein isolation with a multi-electrode radiofrequency balloon catheter in paroxysmal atrial fibrillation: one year outcomes from SHINE. *Europace.* 2021;23(6):851-860.
6. Sylla P, Sagar P, Johnston SS, et al. Outcomes associated with the use of a new powered circular stapler for left-sided colorectal reconstructions: a propensity score matching-adjusted indirect comparison with manual circular staplers. *Surg Endosc.* 2022;36(4):2541-2553. doi:10.1007/s00464-021-08542-7
7. Rawlins L, Johnson BH, Johnston SS, Elangovanraaj N, Bhandari M, Cohen RV, Rheinwalt KP, Fryrear R, Roy S. Comparative effectiveness assessment of two powered surgical stapling platforms in laparoscopic sleeve gastrectomy: a retrospective matched study. *Med Devices (Auckl).* 2020;13:195-204. doi:10.2147/MDER.S256237.
8. National Joint Registry for England, Wales, Northern Ireland and the Isle of Man. Implant Summary Report for DePuy ATTUNE CR and ATTUNE PS. NJR Database extract November 18, 2021. Licensed for use until November 24, 2022. Available at www.ATTUNEvidence.com (US) and www.provingthepromise.com (EMEA).
9. Miller LE, Kamath AF, Boettner F, Bhattacharyya SK. In-hospital outcomes with anterior versus posterior approaches in total hip arthroplasty: meta-analysis of randomized controlled trials. *J Pain Res.* 2018;11:1327-1334. doi:10.2147/JPR.S166058.
10. de Jonge SW, Atema JJ, Solomkin JS, Boermeester MA. Meta-analysis and trial sequential analysis of triclosan-coated sutures for the prevention of surgical site infection. *Brit J Surg.* 2017; 104(2):e118-e133. doi: 10.1002/bjs.104-45
11. de Jonge SW, Atema JJ, Solomkin JS, Boermeester MA. Meta-analysis and trial sequential analysis of triclosan-coated sutures for the prevention of surgical site infection. *Brit J Surg.* 2017;104(2):e118-e133. doi:10.1002/bjs.104-45.
12. Sylla P, Sagar P, Johnston SS, et al. Outcomes associated with the use of a new powered circular stapler for left-sided colorectal reconstructions: a propensity score matching-adjusted indirect comparison with manual circular staplers. *Surg Endosc.* 2022;36(4):2541-2553. doi:10.1007/s00464-021-08542-7
13. Miller LE, Gondusky JS, Bhattacharyya S, Kamath AF, Boettner F, Wright J. Does surgical approach affect outcomes in total hip arthroplasty through 90 days follow-up? A systematic review with meta-analysis. *J Arthroplasty.* 2018;33(4):1296-1302
14. Sylla P, Sagar P, Johnston SS, et al. Outcomes associated with the use of a new powered circular stapler for left-sided colorectal reconstructions: a propensity score matching-adjusted indirect comparison with manual circular staplers. *Surg Endosc.* 2022;36(4):2541-2553. doi:10.1007/s00464-021-08542-7
15. Bunch TJ, May HT, Bair TL, et al. Increasing time between first diagnosis of atrial fibrillation and catheter ablation adversely affects long-term outcomes. *Hear Rhythm.* 2013;10(9):1257-1262. doi:10.1016/j.hrthm.2013.05.013
16. Miller LE, Kamath AF, Boettner F, Bhattacharyya SK. In-hospital outcomes with anterior versus posterior approaches in total hip arthroplasty: meta-analysis of randomized controlled trials. *J Pain Res.* 2018;11:1327-1334. doi:10.2147/JPR.S166058
17. Mark DB, Anstrom KJ, Sheng S, et al. Effect of catheter ablation vs medical therapy on quality of life among patients with atrial fibrillation: the CABANA randomized clinical trial. *JAMA.* 2019;321(13):1275-1285. doi:10.1001/jama.2019.0692
18. NICE 2021. Medical Technologies Guidance: Plus Sutures for preventing surgical site infection. Available from: <https://www.nice.org.uk/guidance/mtg59/resources/plus-sutures-for-preventing-surgical-site-infection-pdf-64372124642245>. Accessed April 1, 2022. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Cautions Concerning Forward-Looking Statements

This document contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. Our “Cautionary Note Regarding Forward-Looking Statements” and “Risk Factors” can be found in *Johnson & Johnson Annual Reports* at jn.com/about-jnj/annual-reports. Neither the Johnson & Johnson MedTech Companies nor Johnson & Johnson undertakes to update any information in this document as a result of new information or future events or developments. Information on annual “Environmental, Social and Governance Disclosures” can be found in the *Johnson & Johnson Health for Humanity Report* at healthforhumanityreport.jn.com.